Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-004228
Filing Date
2025-02-14
Accepted
2025-02-14 18:05:29
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 16764
2 JOINT FILING AGREEMENT ex-99-02142025_110232.htm EX-99.1 6889
  Complete submission text file 0001415889-25-004228.txt   25711
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Subject) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88625 | Film No.: 25631538
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)

Mailing Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036
Business Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036 212-444-4100
Venrock Healthcare Capital Partners III, L.P. (Filed by) CIK: 0001738048 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A